Tampere's LifeGlue Raises €705K to Scale Animal-free Tissue Hydrogel Production
Tampere biotech LifeGlue Technologies has raised €705,000 in seed funding and will build GMP-grade production to scale its animal-free hyaluronic-acid hydrogel for lab-grown tissues toward patient use.
Tampere biotech LifeGlue Technologies has raised €705,000 in seed funding and will build Good Manufacturing Practice (GMP) grade production to scale its animal-free hydrogel for tissue growth toward patient use. The funding was reported by Tamperelainen.
Spun out of Tampere University in December 2024, LifeGlue makes a hyaluronic-acid-based hydrogel used by researchers to grow brain, liver, nerve and fat tissue in the lab. The animal-free material avoids the variability of animal-derived gels and already holds a US patent. The company has 15 paying customers across Europe, the United States and Australia, and its seed round attracted Finnish, Estonian and Lithuanian angel investors alongside an Innovestor co-investment fund.
CEO Laura Kuittinen said LifeGlue aims to be a raw-material supplier for many tissue-technology developers rather than betting on a single therapy, a strategy an investing angel praised for reducing market risk. The next step is building GMP-grade production. Clinical treatments remain years away because lab-grown tissues must pass large-scale safety and efficacy trials.
The raise is another sign of Tampere's growing health-tech scene, following other Tampere health startups winning U.S. clearances and a Tampere University spinout advancing toward clinical trials.
Earlier coverage
Catch the full story over at Tamperelainen